



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)

Hydroxy-PEG3-CH2-Boc

| | | | |
|---------------------------|--|-------|----------|
| Cat. No.: | HY-141209 | | |
| CAS No.: | 518044-31-0 | | |
| Molecular Formula: | C ₁₂ H ₂₄ O ₆ | | |
| Molecular Weight: | 264.32 | | |
| Target: | PROTAC Linkers | | |
| Pathway: | PROTAC | | |
| Storage: | Pure form | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (189.16 mM; Need ultrasonic)

| Solvent | Mass | Concentration | | |
|---------------------------|-------|---------------|------------|------------|
| | | 1 mg | 5 mg | 10 mg |
| Preparing Stock Solutions | 1 mM | 3.7833 mL | 18.9165 mL | 37.8329 mL |
| | 5 mM | 0.7567 mL | 3.7833 mL | 7.5666 mL |
| | 10 mM | 0.3783 mL | 1.8916 mL | 3.7833 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

| | | |
|-------------------------------------|--|-------------|
| Description | Hydroxy-PEG3-CH2-Boc is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs ^[1] . | |
| IC₅₀ & Target | PEGs | Alkyl/ether |
| In Vitro | PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. | |

REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA